Gönül Müzeyyen, Gül Ulker
Department of Dermatology, Ministry of Health Ankara Numune Education and Research Hospital, Ankara, Turkey.
Contact Dermatitis. 2005 Aug;53(2):67-70. doi: 10.1111/j.0105-1873.2005.00638.x.
The delayed hypersensitivity development against topical corticosteroids which are used in allergic contact dermatitis (ACD) treatment is an important clinical problem. In our study, 41 ACD patients who did not show any response to topical corticosteroid treatment were patch tested with corticosteroid series and the commercial preparations of corticosteroids and their vehicles. In corticosteroid series, there were budesonide, bethametasone-17-valerate, triamcinolone acetonide, tixocortol pivalate, alclomethasone-17-21-dipropionate, clobetasole-17-propionate, dexamethasone-21-phosphate disodium and hydrocortisone-17-butyrate. We detected positive reaction to corticosteroids in 9 of our cases (22%) (5 single and 4 multiple). The sensitivity was mostly produced by tixocortol pivalate (6 patients). This was followed by triamcinolone acetonide (2 patients) budesonide (2 patients), alclomethasone dipropionate (2 patients), dexamethasone 21 phosphate disodium (2 patients) and betamethasone-17-valerate (1 patient). As a result, it should not be forgotten that the corticosteroids used to treat ACD patients may cause ACD themselves. In ACD patients who did not respond to corticosteroid treatment, routinely applying patch test with corticosteroids should be helpful in directing the treatment.
用于治疗过敏性接触性皮炎(ACD)的外用糖皮质激素引发的迟发型超敏反应是一个重要的临床问题。在我们的研究中,对41名外用糖皮质激素治疗无反应的ACD患者进行了糖皮质激素系列、糖皮质激素及其赋形剂的商业制剂的斑贴试验。糖皮质激素系列包括布地奈德、倍他米松-17-戊酸酯、曲安奈德、匹伐酸替可的松、二丙酸倍氯米松、丙酸氯倍他索、地塞米松-21-磷酸二钠和丁酸氢化可的松。我们检测到9例患者(22%)(5例单一阳性和4例多重阳性)对糖皮质激素呈阳性反应。敏感性大多由匹伐酸替可的松引起(6例患者)。其次是曲安奈德(2例患者)、布地奈德(2例患者)、二丙酸倍氯米松(2例患者)、地塞米松-21-磷酸二钠(2例患者)和倍他米松-17-戊酸酯(1例患者)。因此,不应忘记用于治疗ACD患者的糖皮质激素本身可能会引起ACD。在对糖皮质激素治疗无反应的ACD患者中,常规进行糖皮质激素斑贴试验有助于指导治疗。